Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Enhancing immunotherapy with tumour-responsive nanomaterials
Stephen W. Linderman
, Louis DeRidder
, Lucía Sanjurjo
, Michael B. Foote
, María José Alonso
,
Ameya R. Kirtane
, Robert Langer
, Giovanni Traverso
Pharmaceutics
Research output
:
Contribution to journal
›
Review article
›
peer-review
127
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Enhancing immunotherapy with tumour-responsive nanomaterials'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Tumor
100%
Responsive Nanomaterials
100%
Nanomaterials
50%
Targeted Delivery
50%
Tumor Microenvironment
50%
Cancer Research
25%
Clinical Translation
25%
Hypoxia
25%
Extracellular Matrix
25%
Chimeric Antigen Receptor T Cells (CAR-T)
25%
Locoregional
25%
Reactive Oxygen Species
25%
Systemic Administration
25%
Specific Enzymes
25%
Cytokine mRNA
25%
Dynamic Properties
25%
Immunogenic Cell Death
25%
Ongoing Clinical Trials
25%
Reductive Conditions
25%
Improved Patient Outcomes
25%
Cargo
25%
Promising Areas
25%
Off-target Toxicity
25%
Immunosuppressive Microenvironment
25%
MRNA Vaccine
25%
Innovative Approaches
25%
Immune Checkpoint Inhibitors
25%
Current Landscape
25%
Transformative Potential
25%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Nanomaterial
100%
Tumor Microenvironment
60%
Clinical Trial
20%
Immune Checkpoint Inhibitor
20%
mRNA Vaccine
20%
Immunogenic Cell Death
20%
Malignant Neoplasm
20%
Hypoxia
20%
Cytokine
20%
Chimeric Antigen Receptor
20%
Immunosuppressive Agent
20%
Reactive Oxygen Metabolite
20%
Systemic Administration
20%
Adenosine Triphosphate
20%
Enzymes
20%
Material Science
Nanostructured Material
100%
Immunotherapy
100%
Adenosinetriphosphate
20%
Antigen
20%
Cell Death
20%